Skip to content

The effect of Mesobotox on erythema and acne scars

A Comparative Evaluation of the Efficacy and Safety of Mesobotox Therapy versus Pulsed Dye Laser (PDL) in the Treatment of Erythema of Acne Scar and Influencing Factors: A Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250302064904N1
Enrollment
20
Registered
2025-07-22
Start date
2025-07-28
Completion date
Unknown
Last updated
2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

????? ???????? ? ??????? ????. Atrophic disorder of skin, unspecified

Interventions

Intervention 1: Intervention Protocol: In this study, botulinum toxin type A (Masport®, Masoon Darou Pharmaceutical Co.) was used for treatment. Each 500-unit vial was initially diluted with 3.4 mL of

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to No maximum

Inclusion criteria

Inclusion criteria: Presenting with moderate to severe erythematous atrophic scarring on both sides of the face.

Exclusion criteria

Exclusion criteria: Use of topical medication on the scar site

Design outcomes

Primary

MeasureTime frame
Acne scar erythema. Timepoint: Evaluation of acne scar erythema will be performed at four time points: before treatment initiation (baseline), then at 1 month, 2 months, and 3 months after Mesobotox treatment. Method of measurement: In this study, standardized clinical photographs of lesions are obtained at four time points: baseline (treatment initiation), 1-month, 2-month, and 3-month follow-ups. All photographic documentation is performed under consistent lighting conditions. These images are subsequently evaluated by two board-certified dermatologists specializing in acne scar management, who grade erythema severity using a validated 4-point scale (0: no erythema, 1: mild erythema, 2: moderate erythema, 3: severe/dark red erythema).Concurrently, Visioface® imaging system documentation is performed at all four evaluation timepoints (baseline, months 1, 2, and 3) to provide objective erythema measurements through standardized facial imaging. Additionally, patients complete a Visual Analog Scale (VAS) for self-assessment of erythema severity at both baseline and treatment completion, where 0 represents minimal erythema and 10 indicates maximal erythema severity. This multimodal assessment approach - incorporating expert clinician ratings, objective Visioface® measurements, and patient-reported outcomes - enables comprehensive longitudinal evaluation of acne scar erythema improvement throughout the treatment course.

Countries

Iran (Islamic Republic of)

Contacts

Public Contact????? ??????? ??????

Tehran University of Medical Sciences

ansarims@sina.tums.ac.ir+98 21 5288 8282

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026